---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-24-000115"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:24:27.070997+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio reports 71% complete response rate in 100-patient ANKTIVA trial; durable responses up to 54 months

## Summary
- 100 patients with BCG-unresponsive NMIBC CIS enrolled; 71% achieved complete response (CR) rate.
- Durable response duration ranged up to 54 months in responders, supporting cystectomy avoidance.
- Updated data to be submitted to EMA in Marketing Authorization Application in Q4 2024.
- CR rate consistent with 71% reported for 82 patients in NEJM Evidence (Chamie 2022).
- Study continues to monitor durability of responses and overall survival outcomes.

## SEC filing metadata
- accession: 0001326110-24-000115
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611024000115/0001326110-24-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611024000115/ibrx-20241119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-24-000115
- JSON: https://secwatch.observer/filing/0001326110-24-000115.json
- Plain text: https://secwatch.observer/filing/0001326110-24-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.